- Coordinator
- Vlaamse Instelling Voor Technologisch Onderzoek N.v., Belgium
- Runs
- 1 November 2025 to 31 October 2028
- Status
- Running
- EU funding
- €5.2m
- Total cost
- €9.4m
- Partners
- 42 organisations in 12 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101219311
What the project is doing
In the project's own words, from its summary on CORDIS.
BRIDGE aims to enhance healthcare innovation in Europe by developing a comprehensive framework for designing and operationalizing regulatory sandboxes. By addressing current regulatory limitations and engaging all stakeholders while ensuring compliance, the project seeks to create adaptable, fit-for-purpose methodologies that strengthen the regulatory ecosystem's capacity to promote healthcare innovation. The project’s objectives include identifying and analysing existing regulatory sandboxes across various domains and maturity levels, to determine how their modules can complement current healthcare regulations.
BRIDGE will develop a horizon scanning methodology to continuously identify emerging technologies that challenge existing regulatory systems, analyzing their requirements for potential inclusion in regulatory sandboxes to ensure adaptability within an evolving innovation ecosystem. Through multi-stakeholder consultations, BRIDGE will elaborate and assess case studies, as well as develop operational checklists for module design and evidence packages to guide tailored sandbox launches.
The project will also develop the Modular Operational Sandbox for Healthcare Innovation and Compliance (MOSAIC), an architectural model with interconnected modules featuring detailed functional specifications and mapped information flows aligned with specific case studies. Additionally, BRIDGE will engage key stakeholders—including regulatory bodies, industry consortia, HTA bodies, payers, healthcare providers, and patients—in an in-depth analysis, consultation, and consensus-building process to ensure the sandbox approach is comprehensive, functional, and adaptable to future advancements.
Finally, the project will deliver comprehensive recommendations for the sandbox methodology’s end-to-end operations, encompassing legal, compliance, policy, and regulatory outputs to provide a robust implementation framework.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Vlaamse Instelling Voor Technologisch Onderzoek N.v. | Mol | Belgium | Coordinator |
| Federation Europeenne D'associations Et D'industries Pharmaceutiques | Bruxelles | Belgium | Participant |
| Janssen Pharmaceutica NV | Beerse | Belgium | Participant |
| MSD Europe Belgium | Brussels | Belgium | Associatedpartner |
| The European Association Medical Devices-Notified Bodies | Sprimont | Belgium | Participant |
| The European Institute for Innovation Through Health Data | Gentbrugge | Belgium | Participant |
| F. Hoffmann-La Roche AG | Basel | Switzerland | Participant |
| Novartis Pharma AG | Basel | Switzerland | Participant |
| Takeda Pharmaceuticals International AG | Glattpark | Switzerland | Participant |
| Bundesinstitut Fur Arzneimittel Und Medizinprodukte | Bonn | Germany | Participant |
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Participant |
| Csl Behring GmbH | Marburg | Germany | Participant |
| Empirica Gesellschaft Fur Kommunikations Und Technologieforschung Mbh | Bonn | Germany | Participant |
| Euroscan International Network eV | Koln | Germany | Participant |
| Lilly Deutschland GmbH | Bad Homburg | Germany | Associatedpartner |
| Merck Healthcare Kgaa | Darmstadt | Germany | Associatedpartner |
| Merck Kommanditgesellschaft Auf Aktien | Darmstadt | Germany | Participant |
| Merckle GmbH | Blaubeuren | Germany | Associatedpartner |
| Pfizer Pharma GmbH | Berlin | Germany | Associatedpartner |
| Sanofi-Aventis Deutschland GmbH | Frankfurt Am Main | Germany | Associatedpartner |
| Technische Universitaet Dresden | Dresden | Germany | Participant |
| Novo Nordisk A/s | Bagsvaerd | Denmark | Participant |
| Fundacion Publica Andaluza Progreso Y Salud M.p. | Sevilla | Spain | Participant |
| Merck, Sharp & Dohme de España, S.A. | Madrid | Spain | Associatedpartner |
| Teknologian Tutkimuskeskus VTT Oy | Espoo | Finland | Participant |
| Sanofi R&d Vaccins | Lyon | France | Associatedpartner |
| Sanofi Winthrop Industrie | Gentilly | France | Associatedpartner |
| Sanofi-Aventis Recherche & Developpement | Gentilly | France | Participant |
| Universite Bourgogne Europe | Dijon | France | Participant |
| Pfizer Healthcare Ireland Unlimited Company | Dublin | Ireland | Associatedpartner |
| Teva Pharmaceutical Industries Limited | Petach Tivka | Israel | Participant |
| Academisch Ziekenhuis Groningen | Groningen | Netherlands | Participant |
| Astellas Pharma Europe BV | Leiden | Netherlands | Participant |
| The European Medicines Agency | Amsterdam | Netherlands | Participant |
| Biogen Idec Limited | Maidenhead | United Kingdom | Participant |
| Eli Lilly and Company Ltd | Basingstoke | United Kingdom | Associatedpartner |
| Msd R&d Innovation Centre Limited | London | United Kingdom | Associatedpartner |
| Merck Serono Ltd. | Feltham | United Kingdom | Associatedpartner |
| Pfizer R&D UK Limited | Sandwich | United Kingdom | Associatedpartner |
| Eli Lilly and Company | Indianapolis | United States | Participant |
| Merck Sharp & Dohme Corp | Whitehouse Station Nj | United States | Participant |
| Pfizer Inc | New York City | United States | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI